Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Purchased by Renaissance Technologies LLC

Renaissance Technologies LLC grew its position in Sana Biotechnology, Inc. (NASDAQ:SANA) by 1,838.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 319,818 shares of the company’s stock after purchasing an additional 303,318 shares during the quarter. Renaissance Technologies LLC owned approximately 0.14% of Sana Biotechnology worth $521,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of SANA. Corient Private Wealth LLC increased its stake in Sana Biotechnology by 161.7% in the fourth quarter. Corient Private Wealth LLC now owns 1,182,699 shares of the company’s stock valued at $1,928,000 after purchasing an additional 730,699 shares during the last quarter. Barclays PLC raised its stake in Sana Biotechnology by 126.6% during the 3rd quarter. Barclays PLC now owns 318,910 shares of the company’s stock worth $1,325,000 after acquiring an additional 178,179 shares in the last quarter. ExodusPoint Capital Management LP lifted its position in Sana Biotechnology by 174.4% in the fourth quarter. ExodusPoint Capital Management LP now owns 272,908 shares of the company’s stock valued at $445,000 after acquiring an additional 173,442 shares during the last quarter. SG Americas Securities LLC acquired a new position in Sana Biotechnology in the fourth quarter valued at $239,000. Finally, Clarius Group LLC grew its holdings in shares of Sana Biotechnology by 78.1% during the fourth quarter. Clarius Group LLC now owns 112,500 shares of the company’s stock worth $183,000 after purchasing an additional 49,316 shares during the last quarter. 88.23% of the stock is owned by hedge funds and other institutional investors.

Sana Biotechnology Stock Performance

Sana Biotechnology stock opened at $1.89 on Friday. Sana Biotechnology, Inc. has a fifty-two week low of $1.26 and a fifty-two week high of $10.50. The firm has a market capitalization of $426.15 million, a price-to-earnings ratio of -1.35 and a beta of 1.78. The stock’s fifty day moving average is $2.01 and its two-hundred day moving average is $2.56.

Sana Biotechnology (NASDAQ:SANA) last posted its earnings results on Monday, March 17th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.02. As a group, sell-side analysts forecast that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on SANA. TD Cowen raised Sana Biotechnology from a “hold” rating to a “buy” rating in a research report on Wednesday, January 8th. Citizens Jmp upgraded shares of Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 target price for the company in a research note on Tuesday, March 18th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Sana Biotechnology in a research note on Thursday, April 24th. Finally, Jefferies Financial Group began coverage on Sana Biotechnology in a research note on Friday, March 14th. They issued a “buy” rating and a $7.00 target price on the stock. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.80.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.